ASX Share rice
Sat 15 Aug 2020 - 03:48:am (Sydney)

NEU Share Price

NEUREN PHARMACEUTICALS LIMITEDNEUPharmaceuticals, Biotechnology & Life Sciences

NEU Company Information

Name:

Neuren Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

697 Burke Road Camberwell Australia 3124

Phone:

61 3 9092 0480

Chief Science Officer:

Mr. Lawrence Glass

Chief Exec. Officer:

Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA

CFO & Company Sec.:

Ms. Lauren Frazer C.A.

Company Overview:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.

NEU Share Price Information

Shares Issued:

119.95M

Market Capitalisation:

$152.94M

Revenue (TTM):

$495K

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.007

Operating Margin (TTM):

$-22.38

Return On Assets (TTM):

$-0.34

Return On Equity (TTM):

$-0.56

Quarterly Revenue Growth (YOY):

-0.965

Gross Profit(TTM):

$-9,363,000

Diluted Earnings Per Share (TTM):

$-0.108

NEU CashFlow Statement

CashFlow Date:

2019-12-31

Investments:

$-12,000

Change To Liabilities:

$-1,414,000

Total Cashflow From Investing Activities:

$-12,000

Net Income:

$-10,816,000

Total Cash From Operating Activities:

$-11,719,000

Depreciation:

$4K

Change To Account Receivables:

$390K

Capital Expenditures:

$12K

NEU Income Statement

Income Date:

2019-12-31

Income Before Tax:

$-10,816,000

Net Income:

$-10,816,000

Gross Profit:

$-9,363,000

Operating Income:

$-11,571,000

Total Revenue:

$495K

Total Operating Expenses:

$11.57M

Cost Of Revenue:

$9.86M

NEU Balance Sheet

Balance Sheet Date:

2019-12-31

Total Liabilities:

$559K

Total Stockholder Equity:

$13.85M

Total Assets:

$14.41M

Common Stock:

$126.43M

Retained Earnings:

$-104,076,000

Cash:

$13.84M

Total Current Liabilities:

$559K

Property - Plant & Equipment:

$10K

Net Tangible Assets:

$13.85M

Total Current Assets:

$14.40M

Net Receivables:

$13K

Short-Term Investments:

$10K

Accounts Payable:

$340K

Non Currrent Assets (Other):

$10K

Short-Term Investments:

$10

Non Current Liabilities Total:

$0

NEU Share Price History

NEU News

03 Jun, 2020
Whilst it may not be a huge deal, we thought it was good to see that the Neuren Pharmaceuticals Limited (ASX:NEU...
19 May, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
03 Mar, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug Application for another product in an expedited period of six months.
18 Feb, 2020
Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...
17 Oct, 2019
Neuren Pharmaceuticals (NEU.AX) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of Angelman syndrome, Phelan-McDermid syndrome and Pitt Hopkins syndrome. Neuren Executive Chairman Richard Treagus commented: “Orphan Drug Designation is an important commercial milestone which adds significant value and momentum in respect of our plans to move NNZ-2591 into clinical trials in 2020. This confirms that NNZ-2591 is a valuable asset for Neuren and validates the encouraging preclinical data as well as our plans to develop NNZ-2591 in parallel for these three debilitating childhood disorders with urgent unmet need.
23 Aug, 2019
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...